Peculiarities of a humoral immune response in coronavirus infection (COVID-19)
Keywords:coronavirus, COVID-19, immunoglobulin, enzyme-linked immunosorbent assay
We reviewed scientific data published during the recent 12 months about peculiarities of a humoral immune response in coronavirus infection (COVID-19). We also examined the concentration of immunoglobulin G against SARS-CoV-2 in 65 people in the Diagnostic Center “MeDIS” in 2020 with the diagnostic titer of specific antibodies. We established that in 3 months after primary examination of serum 60 % of examined patients presented high titers of IgG against SARS-CoV-2 (seropositivity rate > 7) in ELISA test. The highest level of IgG against SARS-CoV-2 in 3 months after the primary examination was revealed in those with a high initial level of antibodies against this virus.
Centers for Disease Control and Prevention. Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html
Deeks J.J., Dinnes J., Takwoingi Y. et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst. Rev. 2020. 6. CD013652.
To K.K., Tsang O.T., Leung W.S. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. 2020. 20. 565.
Wölfel R., Corman V.M., Guggemos W. et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020. 581. 465.
Lynch K.L., Whitman J.D., Lacanienta N.P. et al. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. Clin. Infect. Dis. 2020.
Rijkers G., Murk J.L., Wintermans B. et al. Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections. J. Infect. Dis. 2020. 222. 1265.
Dan J.M., Mateus J., Kato Y. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021.
Isho B., Abe K.T., Zuo M. et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020. 5.
Iyer A.S., Jones F.K., Nodoushani A. et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020. 5.
Gudbjartsson D.F., Norddahl G.L., Melsted P. et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N. Engl. J. Med. 2020. 383. 1724.
Long Q.X., Tang X.J., Shi Q.L. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 2020. 26. 1200.
Lumley S.F., O’Donnell D., Stoesser N.E. et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N. Engl. J. Med. 2020.
Robbiani D.F., Gaebler C., Muecksch F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020. 584. 437.
Wajnberg A., Amanat F., Firpo A. et al.. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020.
Wang K., Long Q.X., Deng H.J. et al. Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection. Clin. Infect. Dis. 2020.
Self W.H., Tenforde M.W., Stubblefield W.B. et al. Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network — 12 States, April — August 2020. MMWR Morb. Mortal. Wkly Rep. 2020. 69. 1762.
Qu J., Wu C., Li X. et al. Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 2020 Apr 27.
Hansen K.E., Caliendo A.M., Arias C.A. et al. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing. Auguest 18, 2020. https://www.idsociety.org/practice-guideline/covid-19-guideline-serology
World Health Organization. Diagnostic testing for SARS-CoV-2: interim guidance. 2020. https://www.who.int/publications/i/item/diagnostic-testing-for-sarscov-2
Coronavirus (COVID-19) Update: FDA Authorizes First Test that Detects Neutralizing Antibodies from Recent or Prior SARS-CoV-2 Infection. November 06, 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-test-detects-neutralizing-antibodies-recent-or
В Україні зареєстровано майже 600 випадків повторних заражень COVID-19. МОЗ України, лютий 2021 року. https://ua.interfax.com.ua/news/general/721590.html
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.